Kino K, Sone T, Watanabe J, Yamashita A, Tsuboi H, Miyajima H, Tsunoo H
Biochemical Genetics Division, Meiji Institute of Health Science, Kanagawa, Japan.
Int J Immunopharmacol. 1991;13(8):1109-15. doi: 10.1016/0192-0561(91)90162-z.
LZ-8, a new and recently discovered immunomodulator from Ganoderma lucidum, has been shown to have immunosuppressive activity in vivo and to be a member of the immunoglobulin superfamily. In this paper we examined the in vivo effect of LZ-8 on antibody production using the hepatitis B surface antigen (HBs Ag) in mice. LZ-8 had mitogenic activity in vitro towards spleen cells of C57BL/10 (B10) and C57BL/10BR (B10BR) as previously shown towards those of DBA/2 mice. B10 and B10BR mice produced anti-HBs Ag antibody by the twice sensitization of the antigen while intraperitoneal administration of LZ-8 twice weekly into the mice (8 and 12 mg/kg) greatly prevented the production of antibody to HBs Ag (83.3-96.8% inhibition). We further examined the effect of LZ-8 administration on mitogen responsibility of spleen cells and on the T-cell subset population in both the spleen and lymph node but no significant differences were observed between the LZ-8 treated and untreated mice. These results suggest that the immunosuppressive activities of LZ-8, previously shown, such as the prevention of systemic anaphylaxis and the Arthus reactions, were caused by the blocking of antigen-specific antibody production.
LZ-8是一种新发现的来自灵芝的免疫调节剂，已被证明在体内具有免疫抑制活性，并且是免疫球蛋白超家族的成员。在本文中，我们使用小鼠体内的乙肝表面抗原（HBs Ag）研究了LZ-8对抗体产生的体内作用。如先前对DBA/2小鼠脾脏细胞所显示的那样，LZ-8在体外对C57BL/10（B10）和C57BL/10BR（B10BR）小鼠的脾脏细胞具有促有丝分裂活性。B10和B10BR小鼠通过抗原的两次致敏产生抗HBs Ag抗体，而每周两次向小鼠腹腔注射LZ-8（8和12 mg/kg）可极大地抑制抗HBs Ag抗体的产生（抑制率为83.3%-96.8%）。我们进一步研究了注射LZ-8对脾脏细胞有丝分裂原反应性以及对脾脏和淋巴结中T细胞亚群数量的影响，但在注射LZ-8的小鼠和未注射的小鼠之间未观察到显著差异。这些结果表明，先前显示的LZ-8的免疫抑制活性，如预防全身性过敏反应和Arthus反应，是由阻断抗原特异性抗体产生所致。
